Retrospective study of the safety of caspofungin in immunocompromised pediatric patients

被引：38

作者：

Franklin, JA

McCormick, J

Flynn, PM

机构：

[1] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA

[2] St Jude Childrens Res Hosp, Dept Pharmaceut, Memphis, TN 38105 USA

[3] Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Knoxville, TN 37996 USA

来源：

PEDIATRIC INFECTIOUS DISEASE JOURNAL | 2003年 / 22卷 / 08期

关键词：

caspofungin; pediatrics; antifungal; immunocompromised patients;

D O I：

10.1097/01.inf.0000078164.80233.14

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Caspofungin is an antifungal medication proved efficacious and well-tolerated in adults. Twenty-five pediatric patients at St. Jude Children's Research Hospital who had received at least one dose of caspofungin were identified, and their records were reviewed retrospectively. Caspofungin was well-tolerated; only three patients experienced any adverse event judged possibly related to drug. Caspofungin appears to be safe in immunocompromised pediatric patients.

引用

收藏

页码：747 / 749

页数：3

相关论文

共 19 条

[11] Zygomycosis in the 1990s in a tertiary-care cancer center [J].

Kontoyiannis, DP ;

Wessel, VC ;

Bodey, GP ;

Rolston, KVI .

CLINICAL INFECTIOUS DISEASES, 2000, 30 (06) :851-856

[12] Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients [J].

Marr, KA ;

Carter, RA ;

Crippa, F ;

Wald, A ;

Corey, L .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (07) :909-917

[13] Invasive fungal infections after allogeneic peripheral blood stem cell transplantation:: incidence and risk factors in 395 patients [J].

Martino, R ;

Subirá, M ;

Rovira, M ;

Solano, C ;

Vázquez, L ;

Sanz, GF ;

Urbano-Ispizua, A ;

Brunet, S ;

De la Cámara, R .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (02) :475-482

[14] NON-CANDIDA FUNGAL-INFECTIONS AFTER BONE-MARROW TRANSPLANTATION - RISK-FACTORS AND OUTCOME [J].

MORRISON, VA ;

HAAKE, RJ ;

WEISDORF, DJ .

AMERICAN JOURNAL OF MEDICINE, 1994, 96 (06) :497-503

[15]

NISSEN DE, 2002, MOSBYS DRUG CONSULT

[16] Discovery of novel antifungal (1,3)-β-D-glucan synthase inhibitors [J].

Onishi, J ;

Meinz, M ;

Thompson, J ;

Curotto, J ;

Dreikorn, S ;

Rosenbach, M ;

Douglas, C ;

Abruzzo, G ;

Flattery, A ;

Kong, L ;

Cabello, A ;

Vicente, F ;

Pelaez, F ;

Diez, MT ;

Martin, I ;

Bills, G ;

Giacobbe, R ;

Dombrowski, A ;

Schwartz, R ;

Morris, S ;

Harris, G ;

Tsipouras, A ;

Wilson, K ;

Kurtz, MB .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) :368-377

[17] Dematiaceous fungi are an increasing cause of human disease [J].

Rossmann, SN ;

Cernoch, PL ;

Davis, JR .

CLINICAL INFECTIOUS DISEASES, 1996, 22 (01) :73-80

[18] In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species [J].

Vazquez, JA ;

Lynch, M ;

Boikov, D ;

Sobel, JD .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (07) :1612-1614

[19]

WALSH TJ, 2002, 42 INT C ANT AG CHEM